| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Rubin Marc is a Director at CRIS, with reported holdings spanning 2 companies. Recent filings cover 2 purchases and 2 sales. Those positions are worth an estimated $187K at current prices.
Rubin Marc's largest disclosed position is in CRIS as Director, worth about $116K. Net of sales, the recent Form 4 record there shows accumulation of 6,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2019 | CRIS Curis Inc | Director | Sell | 18,500 | $1.05 | $19,476.80 | -39.1% | |
| Sep 4, 2018 | GALT Galectin Therapeutics Inc | Director | Sale+OE | 11,900 | $6.58 | $78,255.59 | -36.6% | |
| Dec 8, 2017 | GALT Galectin Therapeutics Inc | Director | Buy | 7,000 | $1.85 | $12,971.70 | +14.4% | |
| Nov 16, 2017 | CRIS Curis Inc | Director | Buy | 25,000 | $0.98 | $24,500.00 | +94.0% |